Investigating the Theranostic Potential of Elementally Matched [ <sup>43</sup> Sc]Sc-PSMA-617 and [ <sup>47</sup> Sc]Sc-PSMA-617
Two chemically identical, PSMA-targeting radioscandium pharmaceuticals demonstrated <i>in vivo</i> stability, specificity and retention in PSMA+ tumor models. A theranostic study showed that a higher <sup>43</sup>Sc PET SUV<sub>mean</sub> was strongly correlated to therapeutic response from the <sup>47</sup>Sc agent, demonstrating that <sup>43</sup>Sc and <sup>47</sup>Sc can be used as an elementally matched theranostic pair.
Authors
- Shelbie Jaylene Cingoranelli (ORCID: https://orcid.org/0009-0002-5578-0342)
- Sharon Samuel (ORCID: https://orcid.org/0000-0002-5211-0661)
- Volkan Tekin (ORCID: https://orcid.org/0000-0002-0264-3814)
- Hailey A. Houson (ORCID: https://orcid.org/0000-0001-8566-2369)
- Suzanne E. Lapi (ORCID: https://orcid.org/0000-0003-0090-0191)
- Emily Putnam
- Grayson R. Gimblet
Institutions
- University of Alabama at Birmingham (US)
Publication Details
- Journal
- Molecular Pharmaceutics
- Published
- 2026-02-18
- DOI
- https://doi.org/10.1021/acs.molpharmaceut.5c01023
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00